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Abstract 
Background: Zimbabwe set up 12 sentinel sites to monitor HIV drug resistance (HIVDR) following the international 
standards for prevention of HIVDR from 2008 to 2010.
Methods: Participants were consecutively enrolled. Blood was collected and used for CD4 count, viral load (VL) and 
pre‑treatment DR (PDR) tests besides routine baseline tests. We analyzed the characteristics of participants enrolled 
into the survey and estimated the point prevalence of PDR and its associated factors among ART initiators in a cross‑
sectional analysis using the baseline data collected from a prospective cohort in 12 purposefully selected sentinel 
sites.
Results: A total of 1728 participants (96 % response rate) were enrolled and 1610 had complete data. Of the 1610 
there were more females (68.7 %) than males (31.3 %). The median CD4 count was 168 cells/mm3 with males hav‑
ing lower values (P = 0.003). Ninety‑six percent of participants had a VL ≥ 1000 copies/ml and the median VL was 
128,000. Previous exposure to antiretroviral drugs (ARVs) was mainly through PMTCT (5 % of the participants). Overall, 
PDR mutations were detected in 6.3 % (95 % CI 5.2–7.7) of the 1480 successfully genotyped participants. However, 
the prevalence of PDR mutations was double for those with previous exposure (12.1 %) to ARVs compared with those 
without previous exposure (5.7 %, P = 0.002).
Conclusions: The results show a moderate level of PDR prevalence among ART initiators. To maintain the efficacy of 
the current first‑line regimens, there is need to strengthen all HIVDR prevention efforts and to conduct further studies 
to investigate optimal strategies that can prolong the efficacy of first‑line ARV regimens in the country.
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Background
As the global scale-up of antiretroviral therapy (ART) 
increases there are growing concerns over the increase in 
the prevalence of human immunodeficiency virus (HIV) 
drug resistance (HIVDR). This is inevitable because of 
HIV’s rapid and error-prone replication, a high muta-
tion rate in the presence of drug selective pressure, sub-
optimal therapy and/or poor adherence to treatment 
schedules, and viral recombination [1]. HIVDR muta-
tions may also be transmitted to ART naïve patients 
from HIV-infected patients who have HIV drug resist-
ant viruses. Thus, some degree of HIVDR should be 
anticipated in patients starting first-line ART. Factors 
contributing to the development of HIVDR are regi-
men- or drug-specific, virus-related, patient-specific 
and programmatic factors [2, 3]. The provision of high-
quality care and treatment, early diagnosis, and consist-
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In response to the concerns over patients in resource-
limited countries developing HIVDR, the World Health 
Organization (WHO) developed a global HIVDR pre-
vention strategy. This strategy recommends countries 
to conduct surveys that focus on identifying program 
and site-specific factors associated with HIVDR devel-
opment, thus enabling site and program interventions 
to alter these factors. This HIVDR prevention strategy 
helps to maximize the long-term efficacy and durability 
of available antiretroviral regimens [4].
Routine testing of transmitted HIVDR is an important 
strategy in monitoring HIVDR in resource-rich countries 
to ensure the HIV-positive patients are prescribed the 
efficacious ART regimens [5]. Unfortunately, this is not 
available for most patients in resource-limited countries. 
Thus addressing this issue using public health approach 
has become a mammoth task to ensure the efficacy of the 
current first-line regimens in these countries.
In support of the ART scaling up and prevention of 
HIVDR emergence and transmission, Zimbabwe estab-
lished 12 sentinel ART sites to monitor the prevalence 
of HIVDR in the period of 2008–2010. The aim of our 
surveys was to establish the prevalence and distribu-
tion of HIVDR, and to identify risk factors associated 
with HIVDR emergence. These surveys are critical to 
the Zimbabwe ART program in providing information 
on the appropriateness of the non-nucleoside reverse 
transcriptase inhibitors (NNRTI) and nucleoside reverse 
transcriptase inhibitors (NRTI) based first-line regimens 
recommended by WHO and interventions for preserving 
these affordable regimens for the years to come. In the 
current report, we analyzed the characteristics of partici-
pants enrolled into the surveys, and estimated the point 
prevalence of Pre-treatment DR (PDR) and its associated 
factors among ART initiators in a cross-sectional analy-
sis using the baseline data collected from a prospective 
cohort in 12 purposefully selected sentinel sites.
Methods
ART site selection and participant enrolment
The ART sites were purposefully selected in a phased 
approach (three sites in 2008, five sites in 2009 and four 
sites in 2010) following the WHO-recommended meth-
ods [6], for a total of 12 sites. After signing the volun-
teer participation consent, participants were recruited 
sequentially as they initiated ART until the pre-deter-
mined sample size of 150 was reached at each site.
Demographic and clinical data collection
Baseline patient socio-demographic and clinical data 
were obtained using a standard interviewer-administered 
questionnaire. Clinical data were assessed for correctness 
and accuracy by the HIVDR technical working group 
while at the same time support visits were provided to 
the sites to verify data submissions.
Specimen collection
Ten millilitres of blood were collected from each par-
ticipant using two ethylene-diamine-tetra-acetic acid 
(EDTA) tubes. One tube was used for routine baseline 
liver function, full blood and CD4 cell count tests and 
preparation of dried blood spot (DBS) specimens for gen-
otyping on-site. Each participant had two DBS cards pre-
pared (One was prepared for backup purpose) and each 
card had five spots containing 50  µl of blood on each 
spot. These DBS specimens were dried overnight, pack-
aged following standard operating procedures (SOPs) 
and transported to the National Microbiology Reference 
Laboratory (NMRL) at ambient temperature where they 
were stored at −80 °C. The other tube was centrifuged on 
site to obtain plasma which was then aliquoted for viral 
load (VL) testing and HIVDR genotyping.
Viral load measurement and HIVDR genotyping
Viral load testing was performed at NMRL using the 
Roche COBAS Taqman HIV-1 version 2 test with High 
Pure extraction system following the manufacturer`s 
instructions. An aliquot of plasma/DBS from each par-
ticipant was shipped on dry ice to the WHO-designated 
DR laboratories, including the national DR laboratory at 
Medical Research Council of Uganda, Entebbe, Uganda; 
the National Institute of Communicable Diseases 
(NICD), South Africa and the specialized DR laboratory 
at CDC, Atlanta, United States for testing using vali-
dated and quality-assured in-house genotyping methods 
[7–9]. Genotyping analyses included both the protease 
(Pro) and reverse transcriptase (RT) gene regions and 
data quality was ensured by following SOPs established 
in the laboratories which include phylogenetic analysis 
to eliminate cross-contaminations. The quality-assured 
consensus sequences generated were then used to iden-
tify DR mutations interpreted using the Stanford HIV 
Drug Resistance Interpretations Algorithm (http://hivdb.
stanford.edu/). The newly obtained HIV-1 pol sequences 
are submitted in the GeneBank and with accession num-
bers pending.
Statistical analyses
Prevalence, frequencies, proportions, odds ratios, strati-
fied analysis and Chi square tests were calculated using 
Epi info 3.5.4 (CDC, Atlanta, 2013) and Microsoft Excel 
®2007 was used to draw graphs. All calculations were 
made at 95 % confidence intervals (CI). Univariate analy-
sis was initially done fitting information into previously 
prepared shell tables and graphs. This was followed by 
bivariate analysis to examine two variables in association 
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with risk factors and outcomes. Stratified analysis was 
done for factors found to be statistically significant in the 
bivariate analysis to control for confounding and identi-
fying effect modification. The analysis was completed in 
Stata v13, with svyset commands to apply inverse proba-
bility weights that account for oversampling of provincial 
PSUs, and to adjust for clustering of observations within 
PSUs and stratification by site.
Results
Site characteristics, and participant demographic 
and clinical characteristics
Participants were enrolled from a Central Hospital, Pro-
vincial Hospital, Private Clinic, District Hospitals, Mis-
sion Hospital, and a Local Authority Clinic. All 12 sites 
were offering comprehensive Opportunistic Infection 
(OI)/ART services. Pre-study site assessment had showed 
that none of the 12 sites had adequate staff based on the 
Zimbabwe OI/ART Standard Operating Procedures 
(December 2006), although they all had the core staff 
for the purpose of initiating and managing participants 
on ART. There were no reported drug stock-outs within 
6 months prior to the survey period. Ninety-six percent 
(1728) of the expected 1800 participants were enrolled at 
baseline with a median site enrolment of 97 %.
The 93.2 % (1610) of enrolled participants had complete 
data which were used for the analysis. Females consti-
tuted 68.7  % (1106) of all participants. Of the 87 report-
ing previous exposure to ARVs, 72.4 % (63) were women 
who had used single-dose nevirapine (NVP) for prevention 
of mother-to-child transmission of HIV (PMTCT). Most 
(70.8  %) participants had no previous exposure to ARVs 
while 5 % had known exposure status, 23.9 % had missing 
information on exposure and 0.4 % were classified as other.
Median CD4 count was 168 cells/mm3 with males hav-
ing lower CD4 count than females (P =  0.003). Median 
VL was 128,000 copies/ml with no significant difference 
between males and females (P = 0.724) (Table 1). Table 1 
highlights the WHO clinical staging for the 1610 partici-
pants (63.9  % were eligible for ART). Fifteen percent of 
participants had a CD4 count less than 100 cells/mm3. Of 
all participants enrolled and commenced on ART, 53.6 % 
were eligible for ART based on a CD4 count <350 cells/
mm3 alone according to the National ART guidelines 
in place during the period of the study. Males were 
more likely to have advanced HIV infection (CD4 count 
<200) at ART initiation than females (OR 1.59; 95 % CI 
1.22–2.07).
We also analyzed ART initiation criteria based on the 
WHO clinical stages in comparison to CD4 count. There 
were 515 patients in the WHO stage 3 or 4 with a CD4 
count <350  cell/mm3, 514 with CD4 count <350  cells/
mm3 in the WHO stage 1 or 2, 100 in the WHO stage 
3 or 4 with CD4 count >350 cells/mm3, and 294 patients 
in the WHO stage 1 or 2 with CD4 count >350. Accord-
ing to the 2010 Zimbabwe National ART guidelines 294 
patients were not eligible for initiation of ART based on 
CD4 count or WHO clinical staging.
HIV‑1 viral load determination and drug resistance 
genotyping
Among the 1610 participants who had completed data-
set, VL data were available for 1463 (90.9  %) partici-
pants while 147 (9.1  %) were missing. Among the 1463 
Table 1 Characteristics of  the 1610 participants in  the 






Missing data 17 (1.1)
Age
Median age (IQR) 36 (30;44)
WHO clinical staging
Stage 1 106 (6.6)
Stage 2 289 (18.0)
Stage 3 951 (59.1)
Stage 4 78 (4.8)
Missing data 186 (11.5)
Previous Antiretroviral drugs (ARVs) exposure
PMTCT 63 (3.9)
ARVs prior to initiation 18 (1.1)
Others 6 (0.4)
No exposure 1139 (70.7)
Missing exposure status 384 (23.9)
CD4 count





 Females 982 (66.31)
 Males 435 (29.36)
<1000 46 (4.33)
Drug resistance mutations
No. with genotyping results 1483
No resistance 1389
NNRTI resistance only 73 (4.9)
NRTI resistance only 18 (1.2)
NRTI + NNRTI resistance 5 (0.3)
PI resistance 10 (0.7)
Any resistance mutation 94 (6.3)
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participants with VL measurements, 1417 (95.7  %) had 
VL levels greater than or equal to 1000 copies/ml while 
46 (4.3  %) were less than 1000  copies/ml. There was 
no difference on VL levels between men and women 
(P = 0.72) (Table 1).
HIV-1 drug resistance genotyping was performed for 
all 1610 specimens and 92 % of the samples (1483) were 
successfully genotyped. Among the genotyped partici-
pants, 93 [6.3 % (95 % CI 5.2–7.7)] had one or more DR 
mutations (Figs. 1, 2). The proportion of participants with 
mutations ranged from 3.0 to 10.3 % at the 12 participat-
ing sites. The prevalence of PDR mutations was com-
parable for men (5.5 %) and women (6.7 %) (P = 0.402). 
The PDR mutations were mainly those against NNRTIs 
(4.9 %). Among the 73 NNRTI mutations identified, the 
most common mutations are K103N (2.7 %) and Y181C 
(0.9 %). These mutations can cause a high level of resist-
ance to efavirenz (EFV) and NVP, the two ARVs that 
are components of the WHO-recommended first-line 
regimens. Twenty NRTI mutations were also identified 
and the most common ones were K219E/N (0.3  %) and 
M184  V (0.3  %). These mutations also can cause high 
level of resistance to NRTI drugs: lamivudine (3TC) 
and emtricitabine (FTC); and a low level of resistance 
to abacavir (ABC) and didanosine (DDI). The former 
two ARVs are part of the current first-line regimens 
recommended by WHO. In Addition, 10 PI mutations 
were identified and the most common ones were N88D 
(0.2  %) and M46I (0.2  %) which can lead to resistance 
to indinavir (IDV), nelfinavir (NFV), lopinavir (LPV) 
and atazanavir (ATV), in which ritonavir-boosted LPV 
(LPV/r) and ATV (ATV/r) are the components of the 
2nd-line regimens recommended by WHO (Fig. 1).
Factors associated with PDR
Among those 93 participants with PDR mutations, 10 
participants had previous exposure and 65 had no pre-
vious exposure to ARVs while 18 had missing data. 
Prevalence of PDR was significantly higher among those 
with previous exposure (12.6 %, 95 % CI 5.9–19.8) than 
those without exposure (5.7 %, 95 % CI 4.0–6.2) to ARVs 
(P = 0.002) and nine of the 10 who had previous exposure 
were women (Table  4). All three participants who had 
been exposed to ART had resistance to NNRTI (K103 N) 
while one had an additional PI mutation (M46I). Simi-
larly, among the 7 women exposed in PMTCT, six had 
NNRTI and one had PI mutations. Among those exposed 
to ARVs there was no statistically significant differ-
ence in the prevalence of PDR mutations between those 
exposed to ARVs [16.7 %; CI 5.4–57.2] and those exposed 
to PMTCT [11  %; CI 4.9–22.9] (P =  0.467). Analysis of 
PDR by CD4 count values (Table 2) showed that 53.8 % 
Fig. 1 Distribution of baseline antiretroviral drug class mutations among the 93 patients enrolled into the pre‑treatment HIV Drug Resistance 
survey in Zimbabwe: 2008–2010
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had CD4 count below 350 cells/mm3. The prevalence of 
PDR among participants with different CD4 counts was 
not different (P = 0.997).
Bivariate analysis showed that only previous exposure 
to ARVs was significantly associated with PDR (OR 2.58, 
95 % CI 1.3–5.12). Other factors which were not signifi-
cantly associated with PDR were female sex (OR 1.22), 
WHO clinical stage 3 or 4 (OR 1.14) and CD4 count <350 
(OR 1.02) (Tables 3, 4).
Discussion
A moderate level (6.3 %) of PDR was identified among the 
participants newly initiating ART in the 12 sentinel ART 
sites in Zimbabwe. The prevalence of PDR was signifi-
cantly higher among those who had previously exposed 
to ARVs than those without. Exposure of ARVs and the 
most previous exposure to ARVs were women enrolled 
into the PMTCT program. Most participants initiated 
ART were in the WHO clinical stage III or IV while 
more than half of all participants had CD4 count below 
350 cells/mm3. Majority of the participants (95.7 %) had 
a VL ≥  1000 copies/ml. The CD4 count, WHO clinical 
stage, VL, age and sex were not significantly associated 
with the detection of PDR among those with these vari-
ables recorded. In this study, men were more likely to 
Fig. 2 Prevalence of pre‑treatment drug resistance mutations among the participants initiating ART and enrolled in the 2008–2010 HIV drug resist‑
ance survey
Table 2 Distribution of pre-treatment drug resistance muta-
tions by CD4 count among enrolled patients, 2008–2010
CD4 count  
(cells/mm3)
Drug resistance mutations (N = 1483)
With mutation (%) Without mutation (%)
<200 33 (2.2) 491 (33)
200–349 17 (1.1) 261 (17.6)
≥350 43 (2.9) 635 (42.8)
Missing 0 (0) 3 (0.2)
Total 93 (6.3) 1390 (93.7)
Table 3 Factors associated with pre-treatment drug resist-
ance mutations among enrolled participants, 2008–2010
* Statistically significant
Variable Mutation No mutation OR 95 % CI
Sex
Female 68 947 1.22 0.76–1.96
Male 25 426
Previous exposure to ARVs
Yes 11 65 2.58 1.30–5.12*
No 65 991
WHO clinical stage
3 or 4 65 887 1.14 0.69–1.88
1 or 2 22 343
CD4 count (cells/mm3)
<350 43 635 1.02 0.6–1.55
≥350 50 752
Viral load (copies/ml)
≥1000 86 1288 0.47 0.14–1.60
<1000 3 21
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have advanced HIV infection at the initiation of ART 
than women, despite the likelihood of having PDR being 
comparable between men and women.
The results of this study are consistent with the findings 
of a multi-centred observational study in six countries, 
including Zimbabwe, which showed drug class-specific 
resistance prevalence of 2.5 % for NRTIs, 3.3 % for NNR-
TIs, 1.3 % for protease inhibitors, and 1.2 % for dual-class 
resistance to NRTIs and NNRTIs [5]. In South Africa 
provincial level studies reported prevalence rates of 4.2 % 
in Gauteng Province, 2.5  % in Cape Town and 3.6  % in 
Free State Province between 2002 and 2004 [10]. These 
values almost mirror what we found in this study. The 
South African study also suggested rising levels of trans-
mitted drug resistance in the region from 3  % (2005/6) 
to 7  % (2007/8) [10]. Other studies in different parts of 
the world have also shown prevalence of HIVDR ranging 
from 3 to 15 % [3, 11, 12].
In our study, there was no association between age, 
sex, clinical stage and CD4 count with PDR. Similarly 
in a study by Hunt et  al. [13], there was no association 
between resistance and CD4 percentage, sex, and WHO 
clinical stage. However, there was an association with 
younger age. Therefore, these factors may not be relevant 
in considering factors associated with having PDR in our 
population despite the non-random distribution of the 
study sites.
The resistance mutations described herein were 
observed after more than 4  years of the availability of 
treatment in the public health sector in Zimbabwe. It 
should be noted that, although access to treatment in the 
public sector began in 2004, ARVs were already available 
in the private sector, notwithstanding the higher cost, 
limited access and non-standardized regimens.
The most common PDR mutations detected in the cur-
rent study were against NNRTIs, and this finding is con-
sistent with the widespread use of this drug class as part 
of Zimbabwe`s National ART Guidelines as the stand-
ard first-line ART regimens, as well as single-dose NVP 
for PMTCT. As Zimbabwe has adopted the Option B+ 
strategy where all HIV-positive pregnant women and 
lactating mothers are commenced on NNRTI-based 
ART and the finding of an association on detecting PDR 
with previous ARV exposure mainly through PMTCT in 
the current study (Tables 3, 4), there is reason to be cau-
tious/alert to the possibility that women/patients having 
resistance to ARVs prior to initiating the standard first-
line ART may be negatively impacted on their treatment 
outcomes. A study by Hammers and others also showed 
that 13 % of patients with previous exposure to ARVs had 
PDR. The authors then proposed still starting patients on 
the standard first-line regimens with closely monitoring of 
VL and/or genotyping at 6 months into the therapy [14]. 
In Zimbabwe this is not possible considering the limited 
resources, such as laboratory capacity where CD4 count 
and VL are not even routinely available to patient services.
Irrespective of whether the observed frequency of PDR 
mutations is predominantly caused by transmission or 
by selection of undisclosed medication with ARVs, PDR 
mutations in patients who are starting ART may trans-
late into reduced efficacy of the first-line and second-line 
ART regimens. As higher ART coverages are achieved as 
projected, the risk of transmitted HIVDR is likely to be 
increased.
There are limitations of the current study. Firstly, the 
sites were not randomly selected to represent all people 
living with HIV and AIDS in their respective regions. 
Thus caution is warranted when extrapolating the results 
to different subpopulations or regions. Secondly, partici-
pants were chronically infected and eligible for ART ini-
tiation, thus observed PDR may have been transmitted 
or acquired during earlier undisclosed ART or PMTCT. 
Thirdly, due to the design of study to enrol chronically 
HIV infected participants, the PDR prevalence reported 
here may be underestimated, thus the true prevalence of 
PDR might be higher than reported here. However, given 
the challenges of identifying individuals with recent HIV 
infections in resource-limited countries, there are values 
in surveying PDR in populations initiating ART in which 
at least a proxy of PDR in pre-treatment populations 
can be estimated using national representative sampling 
method which will provide important information about 
the probable effectiveness of currently available first-line 
regimens for each country/region to ensure the effective-
ness of national/regional ART programs.
Table 4 Prevalence of  Pre-treatment drug resistance 
mutations among enrolled participants, 2008–2010








3 or 4 6.8 5.3–8.6
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Conclusions
In conclusion, this cross-sectional PDR survey in ART 
initiators at 12 purposefully selected sentinel ART sites 
reveals a moderate level of PDR among the survey par-
ticipants. To maintain the efficacy of the current first-line 
regimens there is need to strengthen all HIVDR pre-
vention efforts and to conduct further studies to inves-
tigate optimal strategies that can prolong the efficacy of 
the current first-line ARV regimens in Zimbabwe and 
beyond.
Abbreviations
3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; ARVs: antiretroviral 
drugs; ATV: atazanavir; CD4: cluster of differentiation; CDC: Centers for Disease 
Control and Prevention; CI: confidence interval; DBS: dried blood spot; DDI: 
didanosine; EDTA: ethylene‑diamine‑tetra‑acetic acid; EFV: efavirenz; FTC: 
emtricitabine; HIV: human immunodeficiency virus; HIVDR: human immu‑
nodeficiency virus drug resistance; LPV: lopinavir; LPV/r: ritonavir‑boosted 
lopinavir; NFV: nelfinavir; NICD: National Institute of Communicable Diseases; 
NMRL: National Microbiology Reference Laboratory; NNRTI: non‑nucleoside 
reverse transcriptase inhibitors; NRTI: nucleoside reverse transcriptase inhibi‑
tors; NVP: nevirapine; OI/ART: opportunistic infection/antiretroviral therapy; 
OR: odds ratio; PDR: pre‑treatment drug resistance; PI: protease inhibitor; 
PMTCT: prevention of mother‑to‑child transmission of HIV; RT: reverse 
transcriptase; SOP: standard operating procedures; VL: viral load; WHO: World 
Health Organization.
Authors’ contributions
MM, MM2, EG, JD, JD2, PM, SN, CY, MW: conception, design, acquisition, data 
collection, analysis and interpretation of data and drafting the manuscript. JS 
and CY: protocol design, laboratory testing of samples, interpretation of the 
laboratory results, data analysis; TA, OM, PHK, CC, GS, MT had oversight of all 
stages of the research and critically reviewed the final draft for important intel‑
lectual content. All authors read and approved the final manuscript.
Author details
1 Ministry of Health and Child Care, Harare, Zimbabwe. 2 Centers for Disease 
Control and Prevention, Harare, Zimbabwe. 3 World Health Organization, 
Harare, Zimbabwe. 4 Department of Community Medicine, University of Zim‑
babwe, Harare, Zimbabwe. 5 National Microbiology Reference Laboratory 
(NMRL), Harare, Zimbabwe. 6 Center for Disease Control and Prevention, 
Atlanta, GA, USA. 7 Newlands Clinic, Harare, Zimbabwe. 
Acknowledgements
This research was supported by the following people and organisations 
both intellectually and financially: Provincial Medical Directors in Zimbabwe, 
Healthcare workers in the various centres participating in the survey and the 
participants who spend their time participating.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Raw data can be made available on request to the corresponding author.
Disclaimer
Use of trade names is for identification only and does not constitute endorse‑
ment by the U.S. Department of Health and Human Services, the Public Health 
Service, or the Centers for Disease control and Prevention. The findings and 
conclusions in this report are those of the author(s) and do not necessarily 
represent the official position of [the Centers for Disease Control and Preven‑
tion/the Agency for Toxic Substances and Disease Registry].
Ethics approval and consent to participate
The protocol was approved by the Medical Research Council of Zimbabwe. 
The anonymous testing of plasma/DBS samples for the current study at the 
Centers for Disease Control and Prevention (CDC) was determined as non‑
human subjects research by the Associate Director for Science at the Center 
for Global Health, CDC, Atlanta, GA, USA.
Funding
This project was supported by the President’s Emergency Plan for AIDS Relief 
(PEPFAR) through US Centers for Disease Control and Prevention Cooperative 
Agreement Number 1U2GGH000315‑03.
Received: 29 September 2015   Accepted: 25 May 2016
References
 1. Coffin JM. HIV population dynamics in vivo: implications for genetic varia‑
tion, pathogenesis, and therapy. Science. 1995;267(5197):483–9.
 2. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023–35. 
doi:10.1056/NEJM200406243502621.
 3. WHO. WHO HIV drug resistance report 2012. Geneva: World Health 
Organisation; 2012.
 4. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health 
Organisation’s global strategy for prevention and assessment on HIV drug 
resistance. Antivir Ther. 2008;13(2):1–13.
 5. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes 
ME, Wellington M, Osiboqun A, Siqaloff KC, Nankya I, Schuurman R, 
Wit FW, Stevens WS, van Vuqt M, de Wit TF. HIV‑1 drug resistance in 
antiretroviral‑naive individuals in sub‑Saharan Africa after rollout of 
antiretroviral therapy: a multicentre observational study. Lancet Infect 
Dis. 2011;11:750–9. doi:10.1016/S1473‑3099(11)70149‑9.
 6. Jordan MR, Bennet DE, Winberg MA, Havlir D, Hammer S, Yang C, Morris L, 
Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng 
E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriens J, McClure CM, 
Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. Update 
on World Health Organization HIV drug resistance prevention and 
assessment strategy: 2004–2011. Clin Infect Dis. 2012;54(Suppl 4):S245–9. 
doi:10.1093/cid/cis206.
 7. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Karidia D, Nguyen DB, Bassey 
O, Ugbena R, Wadonda‑Kabondo N, McConnell MS, Zulu I, Chilima B, 
Nkengasong J, Yang C. Optimization of a low cost and broadly sensitive 
genotyping assay for HIV‑1 drug resistance surveillance and monitoring 
in resource‑limited settings. PLoS One. 2011;6(11):e28184. doi:10.1371/
journal.pone.0028184.
 8. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Signh B, Makubalo L, Bennett 
DE, Morris L. Antiretroviral drug resistance surveillance among drug‑naive 
HIV‑1 infected individuals in Gauteng Province, South Africa in 2002 and 
2004. Antivir Ther. 2008;13:101–7.
 9. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, 
Sanders E, Anzala O, Bekker LG, Stevens G, de Wit TF, Stevens W. Afford‑
able in‑house antiretroviral drug resistance assay with good performance 
in non‑subtype B HIV‑1. J Virol Methods. 2010;163:505–8. doi:10.1016/j.
jviromet.2009.11.011.
 10. Nwobegahay J, Bessong P, Masebe T, Mavhandu L, Manhaeve C, Ndjeka 
N, Selabe G. Prevalence of drug‑resistant mutations in newly diagnosed 
drug‑naïve HIV‑1 infected individuals in a treatment site in the Waterberg 
district, Limpopo province. S Afr Med J. 2011;101:335–7.
 11. Daar ES, Richman DD. Confronting the emergence of drug resistant HIV 
type 1: impact of antiretroviral therapy on individual and population 
resistance. AIDS Res Hum Retrovir. 2005;21:343–57.
 12. Pillay D. Current patterns in the epidemiology of primary HIV drug resist‑
ance in North America and Europe. Antivir Ther. 2004;9:695–702.
 13. Hunt GH, Coovadia A, Abrams AJ, Sherman G, Meyers T, Morris L, et al. 
HIV‑1 drug resistance at antiretroviral treatment initiation in children 
previously exposed to single‑dose nevirapine. AIDS. 2011;25(12):1461–9. 
doi:10.1097/QAD.0b013e3283492180.
 14. Kambugu A. Pre‑ART HIV resistance testing in Africa: are we there yet? 
Lancet Infect Dis. 2012;12:261. doi:10.1016/S1473‑3099(11)70280‑8.
